India, Oct. 7 -- Clinical trials are a key driver of biotech stocks. Every new therapy must pass through a series of testing, Phase 1, Phase 2, and Phase 3, before it is approved and available to patients. Each phase has a distinct purpose, timeline, and risk profile. For investors, understanding these phases is critical as trial readouts often trigger the sharpest stock moves in the sector.
Biotech valuations often move more on clinical data than on earnings, partnerships, or guidance. A single dataset can redefine a company's future, attract Big Pharma interest, or eliminate years of market value overnight. This is why clinical trial literacy is one of the most important skills for biotech investors.
This guide explains what each phase ...